90-Day Peptide Transformation Protocol: Phased Approach for Body Composition and Energy

Ninety days is the minimum meaningful timeframe for peptide-driven transformation. Enough time for GH secretagogues to meaningfully shift body composition. Enough time for collagen peptides to structurally remodel skin and connective tissue. Enough time to establish and evaluate the habit systems that make peptide use sustainable.

This protocol is designed as a phased, escalating approach — starting conservatively, adding compounds as tolerance is established, and including specific blood work checkpoints to ensure you're progressing safely and effectively.

The Three-Phase Framework

Transformation happens in overlapping layers, not all at once. The 90-day protocol divides into three 30-day phases:

Phase 1 (Days 1–30): Foundation — Establish GH secretagogue baseline, begin tissue repair compounds, collect baseline data.

Phase 2 (Days 31–60): Amplification — Add targeted compounds for specific goals, optimize timing, increase doses if Phase 1 was well-tolerated.

Phase 3 (Days 61–90): Integration and Assessment — Refine the protocol based on real data, add seasonal or goal-specific compounds, begin planning the transition to a maintenance or cycling phase.

Before You Begin: Baseline Blood Work

Transformation protocols require data. Without baseline labs, you cannot know whether your protocol is improving, maintaining, or inadvertently worsening key biomarkers. Draw the following before Day 1:

Required:

• IGF-1 (reflects cumulative GH secretion)
• Fasting glucose and insulin (GH peptides can mildly affect insulin sensitivity)
• Testosterone (total and free) and estradiol
• Complete blood count (CBC)
• Comprehensive metabolic panel (CMP)

Recommended:

• hsCRP (inflammatory marker — useful for tracking BPC-157's anti-inflammatory effects)
• TSH and free T4 (thyroid baseline)
• 25(OH)D (vitamin D level)
• Cortisol (morning, for adrenal axis context)

Repeat IGF-1, fasting glucose/insulin, and hsCRP at Day 45 and Day 90. The full panel is repeated at Day 90.

Phase 1 (Days 1–30): Foundation Stack

Pre-bed daily:

• CJC-1295 (no DAC) 100 mcg + Ipamorelin 200 mcg subcutaneous

Morning fasted (start Day 8, once pre-bed injection is established):

• CJC-1295 100 mcg + Ipamorelin 100 mcg subcutaneous

Daily (with breakfast):

• Vitamin D3 3,000–5,000 IU + K2 150 mcg
• Omega-3s 2–4 g EPA+DHA
• Magnesium glycinate 300 mg (evening)

Optional (3x/week for musculoskeletal support):

• BPC-157 250 mcg subcutaneous

Phase 1 tracking metrics (daily):

• Morning body weight (post-bathroom, fasted)
• Sleep quality 1–10
• Energy on waking 1–10
• Workout performance (weight lifted, sets completed, perceived exertion)
• Recovery score (DOMS severity, 1–10)

Phase 1 expected outcomes:

• Improved sleep depth and recovery within 2 weeks
• Water weight normalization (slight initial gain followed by reduction)
• Early body composition signals by day 21–28

Phase 2 (Days 31–60): Amplification

By Day 31, you have established the protocol habit and have 30 days of tracking data. Now you amplify.

Additions based on primary goal:

For body recomposition (fat loss while building lean mass):

• Add AOD-9604 200–300 mcg subcutaneous fasted morning (take 30 minutes before CJC/Ipamorelin or as a standalone fasted dose)
• Increase Ipamorelin to 300 mcg at pre-bed injection if well-tolerated in Phase 1

For tissue repair and athletic performance:

• Increase BPC-157 to 500 mcg daily if using 3x/week in Phase 1
• Add TB-500 2 mg subcutaneous 2x/week for the first 4 weeks of Phase 2, then reduce to 1x/week

For skin, collagen, and anti-aging focus:

• Add GHK-Cu 2–4 mg subcutaneous 3x/week
• Add hydrolyzed collagen peptides 15 g with 250 mg vitamin C, 45 minutes pre-workout or morning

For immune and longevity focus:

• Add TA-1 1 mg subcutaneous 2–3x/week for a full 8-week course
• Add Epithalon 5 mg nightly for a 10-day course within Phase 2

Phase 2 blood work checkpoint (Day 45):

• IGF-1, fasting glucose, fasting insulin
• If IGF-1 has risen more than 30% above baseline or is above reference range, reduce GH peptide doses
• If fasting glucose has risen more than 10 mg/dL, consider removing the morning GH peptide pulse and keeping only the pre-bed injection

Phase 2 Expected Outcomes

By Day 60, measurable body composition changes should be visible:

• Lean mass: 1–3 lbs net gain (on maintenance or slight surplus calories)
• Body fat: Measurable reduction at consistent measurement points (waist, hips, body fat percentage via calipers or DEXA if available)
• Sleep: Consistent improvement over Phase 1 baseline
• Recovery: Significant reduction in DOMS, faster workout performance recovery
• Skin: Visible improvement in firmness and texture if GHK-Cu is included

If none of these are present by Day 60, the primary variables to investigate are: peptide quality (source verification), reconstitution accuracy (dilution calculations), injection technique, and dietary context (peptides work significantly better in a nutrition-optimized environment).

Phase 3 (Days 61–90): Integration and Assessment

Phase 3 is about refining and integrating what's working. Stop adding new compounds; optimize what you have.

Phase 3 protocol adjustments:

• If body composition is trending well: maintain Phase 2 doses
• If sleep quality has plateaued: add DSIP for a 2–3 week course within Phase 3
• If recovery is the remaining gap: prioritize BPC-157 timing around training, ensure collagen + vitamin C pre-workout timing is consistent
• If energy is the remaining gap: consider Semax intranasal 400–600 mcg on high-demand mornings

Phase 3 training optimization: Escalating GH peptide doses during higher training volume periods makes physiological sense. Weeks within Phase 3 that have higher training volume and caloric intake will extract more from the GH protocol than deload weeks. Synchronize your most intense training weeks with the middle of Phase 3, then begin a deload in the final week.

See peptide deload week protocol for how to reduce doses intelligently during a deload.

Day 90 Assessment: The Full Evaluation

At Day 90, repeat all baseline blood work and conduct a systematic comparison:

Objective markers:

• IGF-1 (should be within normal range, ideally upper quartile if in reference range)
• Body weight and composition measurements
• Performance metrics from training log

Subjective markers:

• Average sleep quality vs. Phase 1 baseline
• Average energy vs. Phase 1 baseline
• Average recovery score vs. Phase 1 baseline
• Subjective skin quality, joint comfort, and overall wellbeing

Decision framework for what comes next:

• Results strong, blood work normal → Continue into a 90-day maintenance phase with reduced doses
• Results moderate → Identify the limiting factor (usually nutrition, sleep hygiene, or dose/timing optimization) before repeating
• Results minimal despite full compliance → Consider IGF-1 and GH stimulation testing to rule out underlying GH deficiency requiring medical management

90-Day Nutrition Framework

Peptides amplify your nutritional environment; they don't replace it. For body recomposition, the most effective nutritional context is:

• Protein: 0.8–1.2 g per lb of body weight daily
• Caloric intake: Maintenance to 200 calories above for lean mass focus; 200–400 below for fat loss focus
• Meal timing: Respect the pre-injection fasting windows (2–3 hours before GH peptide injections)
• Prioritize whole foods and minimize ultra-processed food that drives insulin dysregulation

For the full annual context of how this 90-day block fits, read annual peptide cycling plan. For a beginner-focused entry point, start with the 30-day peptide challenge first.

Frequently Asked Questions

Q: Can I run this protocol during a caloric deficit for fat loss? Yes, with modifications. Remove AOD-9604 is unnecessary during a caloric deficit since fat mobilization will be occurring naturally. Keep CJC/Ipamorelin at full dose — GH secretagogues are particularly valuable for lean mass preservation during deficit phases.

Q: What if my IGF-1 is already at the high end of normal range before I start? Start at lower doses — CJC-1295 100 mcg once daily (evenings only) and reduce Ipamorelin to 100 mcg. Recheck IGF-1 at 45 days. If it rises further above the upper reference limit, discontinue GH peptides and focus on BPC-157, GHK-Cu, and TA-1 instead.

Q: Is 90 days of continuous GH secretagogue use safe? The clinical data available suggests continuous use for 3–6 months is well-tolerated when doses are kept within the ranges that maintain IGF-1 within normal reference ranges. Some practitioners prefer a deload week every 8 weeks within longer protocols.

Q: How much of the transformation is from peptides vs. training and diet? Peptides create an amplifying environment. Training and diet are still the primary drivers of body composition change. Realistically, peptides may account for 20–40% of the improvement seen compared to an identical training and diet program without them.

Q: When will I start seeing visible physical changes? For body composition: measurable changes by Day 30, visible changes by Day 45–60 for most people with consistent training and diet. For skin quality: measurable improvement in firmness typically appears within 4–6 weeks of GHK-Cu addition.